Inner Banner

Weekly dose of erlotinib shows decreased duodenal polyp burden

A phase 2 trial tested a de-intensified treatment approach using once-weekly erlotinib in familial adenomatous polyposis (FAP) patients. The treatment reduced d..

3/9/2025 77 read more

Mevrometostat Plus Enzalutamide Confers a Survival Benefit for Patients With Hormone-Refractory mCRP..

A phase 1/2 trial showed that combining mevrometostat with enzalutamide significantly extended progression-free survival (PFS) in metastatic castration-resistan..

2/2/2025 104 read more

ALK Tyrosine Kinase Inhibitors and Weight Gain

Cancer cachexia, first defined in 1858, causes significant weight loss in cancer patients and impacts treatment outcomes. Ponsegromab, an antibody against growt..

1/9/2025 59 read more

Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation ..

The 10-year results of the FOWARC trial showed that neoadjuvant modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) with or without radiati..

12/1/2024 48 read more

Regorafenib delays disease progression in patients with soft tissue sarcoma

The EREMISS phase II trial presented at ESMO Congress 2024 showed that regorafenib significantly delayed disease progression in patients with metastatic or loca..

9/13/2024 53 read more

Checkpoint inhibition improves outcomes in high-risk, locally advanced cervical cancer

The KEYNOTE-A18 study presented at ESMO 2023 showed that combining pembrolizumab with concurrent chemoradiotherapy (CCRT) significantly improved progression-fre..

10/23/2023 66 read more

CAPTIVATE Reveal Effectiveness, Durability of Combination Ibrutinib/Venetoclax for CLL

The 3-year follow-up results from the CAPTIVATE trial showed that the combination of ibrutinib and venetoclax in treatment-naive chronic lymphocytic leukemia (C..

5/26/2022 44 read more